Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 57PARP inhibition in cancer therapyBRCA gene mutations in cancerMetal complexes synthesis and properties

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer

Open access

Published version of a preprint

Abstract

Purpose: Our preclinical studies showed that the PARP inhibitor, olaparib, prior to carboplatin attenuated carboplatin cytotoxicity. We evaluated sequence-specific pharmacokinetic and pharmacodynamic effects, safety, and activity of the combination. Experimental Design: Eligible patients had metastatic or recurrent women's cancer. Olaparib tablets were introduced (100 or 200 mg twice daily, days 1–7) in a 3 + 3 dose escalation with carboplatin AUC4 or 5 every 21 days, up to eight cycles, followed by olaparib 300 mg twice daily maintenance. Patients were randomly assigned to starting schedule: cohort A (olaparib days 1–7, carboplatin on day 8) or B (carboplatin on day 1, olaparib days 2–8) during cycle 1. Patients received the reversed scheme in cycle 2. Blood was collected for olaparib pharmacokinetics, platinum–DNA adducts, comet assay, and PAR concentrations. The primary objectives were to examine schedule-dependent effects on olaparib pharmacokinetics and platinum–DNA adducts. Results: A total of 77 (60 ovarian, 14 breast, and 3 uterine cancer) patients were treated. Dose-limiting toxicity was thrombocytopenia and neutropenia, defining olaparib 200 mg twice daily + carboplatin AUC4 as the MTD. Olaparib clearance was increased approximately 50% when carboplatin was given 24 hours before olaparib. In vitro experiments demonstrated carboplatin preexposure increased olaparib clearance due to intracellular olaparib uptake. Quantities of platinum–DNA adducts were not different as a function of the order of drug administration. Responses included 2 CRs and 31 PRs (46%) with a higher RR in BRCA mutation carriers compared with nonmutation carriers (68% vs. 19%). Conclusions: Tablet olaparib with carboplatin is a safe and active combination. Carboplatin preexposure causes intracellular olaparib accumulation reducing bioavailable olaparib, suggesting carboplatin should be administered prior to olaparib. Clin Cancer Res; 23(6); 1397–406. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-1546

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 57

Metadata

Authors
Lee, J.-M., Peer, C. J., Yu, M., Amable, L., Gordon, N., Annunziata, C. M., Houston, N., Goey, A. K. L., Sissung, T. M., Parker, B., Minasian, L., Chiou, V. L., Murphy, R. F., Widemann, B. C., Figg, W. D., & Kohn, E. C.
Affiliations
  • National Cancer Institute (US)
  • National Institute on Minority Health and Health Disparities (US)
  • National Institutes of Health (US)
Corresponding author
Lee, Jung-Min
Venue
Clinical Cancer Research
Published
2017-03-14
Volume
23
Issue
6
Pages
1397-1406
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2521351716
Cited by
56
References
34
Citations by year
2026: 1 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 6 · 2021: 4 · 2020: 8 · 2019: 6 · 2018: 9 · 2017: 7
FWCI
3.96
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (ZIABC011525)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords
olaparib, carboplatin, PARP inhibitors, drug sequence, pharmacokinetics, pharmacodynamics, platinum-DNA adducts, ovarian cancer, breast cancer, uterine cancer, BRCA mutation carriers, dose-limiting toxicity, thrombocytopenia, neutropenia, intracellular drug accumulation, maintenance therapy, women's cancer, combination chemotherapy, dose escalation
MeSH terms
Adult, Aged, Breast Neoplasms, Drug Administration Schedule, Female, Humans, Leukocytes, Mononuclear, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Phthalazines, Piperazines, Uterine Neoplasms, Carboplatin, DNA Adducts, Maximum Tolerated Dose, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1546
The paper
Lee, J.-M., Peer, C. J., Yu, M., Amable, L., Gordon, N., Annunziata, C. M., Houston, N., Goey, A. K. L., Sissung, T. M., Parker, B., Minasian, L., Chiou, V. L., Murphy, R. F., Widemann, B. C., Figg, W. D., & Kohn, E. C. (2017). Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.